Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 1, 2016, Pages 61-72

  Flores Montero, Juan ^a   de Tute, Ruth ^b   Paiva, Bruno ^c   Perez, José Juan ^d   Böttcher, Sebastian ^e   Wind, Henk ^f   Sanoja, Luzalba ^a   Puig, Noemí ^d   Lecrevisse, Quentin ^a   Vidriales, María Belén ^d   van Dongen, Jacques J M ^f   Orfao, Alberto ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CSIC   (Spain)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

antibody panels; EuroFlow; high sensitivity; markers; minimal residual disease; multiple myeloma

Indexed keywords

ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD200 ANTIGEN; CD22 ANTIGEN; CD229 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD307 ANTIGEN; CD319 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; CYTOPLASMIC IMMUNOGLOBULIN; FLUOROCHROME; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; BONE MARROW; CLONAL VARIATION; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; REVIEW; STAINING; CELL CLONE; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MORTALITY; NEOPLASM, RESIDUAL; PATHOLOGY; PROGNOSIS; REMISSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; SURVIVAL ANALYSIS;

ANTIBODIES; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CLONE CELLS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PLASMA CELLS; PROGNOSIS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 85010982932     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21265     Document Type: Review

References (75)

1. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA Morgan GJ. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095–3100.
2. San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, Hernandez J, Moro MJ, Fernandez-Calvo J, Diaz-Mediavilla J, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853–1856.
3. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood 2015;125:3059–3068.
4. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–1975.
5. Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A. Overview of clinical flow cytometry data analysis: Recent advances and future challenges. Trends Biotechnol 2013;31:415–425.
6. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, Rosinol L, Montejano L, Blade J, Martinez R, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–2744.
7. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. Report of the European myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431–438.
8. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, Vidriales MB, Lopez-Berges MC, Miguel JF, Orfao A. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010;78:239–252.
9. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2:409–417.
10. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:1627–1633.
11. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540–2547.
12. Mathis S, Chapuis N, Borgeot J, Maynadie M, Fontenay M, Bene MC, Guy J, Bardet V. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Cytometry B Clin Cytom 2015;88:101–109.
13. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: Major heterogeneity. Blood 2013;122:1088–1089.
14. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984;63:1424–1433.
15. San Miguel JF, Caballero MD, Gonzalez M, Zola H, Lopez Borrasca A. Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. Br J Haematol 1986;62:75–83.
16. Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, Funaro A, Horenstein AL, Malavasi F. CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom 2013;84:207–217.
17. Campana D, Suzuki T, Todisco E, Kitanaka A. CD38 in hematopoiesis. Chem Immunol 2000;75:169–188.
18. Quijano S, Lopez A, Rasillo A, Barrena S, Luz Sanchez M, Flores J, Fernandez C, Sayagues JM, Osuna CS, Fernandez N, et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: Analysis of a series of 432 patients. Blood 2008;111:5130–5141.
19. Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, Vogt RF Jr., Marti GE, Rawstron AC, Van Zelm MC, et al. Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytometry B Clin Cytom 2010;78 (Suppl 1):S47–S60.
20. Braylan RC. Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasias. Cytometry A 2004;58:57–61.
21. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990;76:1739–1747.
22. Orfao A, Garcia-Sanz R, Lopez-Berges MC, Belen Vidriales M, Gonzalez M, Caballero MD, San Miguel JF. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994;17:332−339.
23. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94:318–323.
24. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998;100:637–646.
25. San Antonio JD, Karnovsky MJ, Gay S, Sanderson RD, Lander AD. Interactions of syndecan-1 and heparin with human collagens. Glycobiology 1994;4:327–332.
26. Yang Y, Borset M, Langford JK, Sanderson RD. Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface. J Biol Chem 2003;278:12888–12893.
27. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonca A, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26:1986–2010.
28. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG III, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev 2015;29:81–91.
29. Khagi Y, Mark TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther 2014;7:1095–1100.
30. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525–542.
31. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014;20:4574–4583.
32. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552–559.
33. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953–1959.
34. Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009;113:4309–4318.
35. Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 2011;96:1512–1520.
36. Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 2013;88:168–177.
37. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231–242.
38. Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, Bottcher S, van Dongen JJM, Orfao A, on behalf of the EuroFlow consortium. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patient with clonal plasma cell diseases. Cytometry B Clin Cytom 2015; DOI 10.1002/cyto.b.21269.
39. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006;6:741–750.
40. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010;95:1016–1020.
41. Perez-Andres M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, Valet G, Kraan J, Gratama JW, D'Hautcourt JL, et al. Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. J Biol Regul Homeost Agents 2004;18:392–398.
42. Robillard N, Wuilleme S, Moreau P, Bene MC. Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol 2014;5:137.
43. Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G, Preffer F. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom 2010;78:231–238.
44. Paiva B, Gutierrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L, Oriol A, Martinez-Lopez J, Mateos MV, Lopez-Corral L, et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012;26:1862–1869.
45. Pojero F, Casuccio A, Parrino MF, Cardinale G, Colonna Romano G, Caruso C, Gervasi F. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual plasma cell analysis. Cytometry B Clin Cytom 2015;88:165–182.
46. Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 1996;95:489–493.
47. San Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 1995;8:735–759.
48. Ruiz-Arguelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc 1994;69:684–690.
49. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML, Hernandez JM, Lopez-Berges MC, Montejano L, Blade J, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005;11:3661–3667.
50. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005;19:1376–1383.
51. Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 2012;137:93–100.
52. Iqbal MS, Otsuyama K, Shamsasenjan K, Asaoku H, Mahmoud MS, Gondo T, Kawano MM. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow. Eur J Haematol 2009;83:302–312.
53. Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, Yu SF, McBride J, de Tute R, Rawstron A, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther 2012;11:2222–2232.
54. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 2007;21:169–174.
55. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482–488.
56. Mahnke YD, Roederer M. Optimizing a multicolor immunophenotyping assay. Clin Lab Med 2007;27:469–485.
57. McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Oxford C, Evans TG, et al. Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry A 2008;73:400–410.
58. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017–4023.
59. Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA. Immunophenotypic heterogeneity of normal plasma cells: Comparison with minimal residual plasma cell myeloma. J Clin Pathol 2012;65:823–829.
60. Schmidt-Hieber M, Paiva B, Perez-Andres M, Gutierrez ML, Dybkaer K, Rasillo A, Tabernero MD, Lopez A, Kryukov F, Carrasco P, et al. CD56+ clonal plasma cells in multiple myeloma are associated with unique disease characteristics and have a counterpart of CD56+ normal plasma cells with increased maturity. Abstract Blood 2013;122:751–751.
61. Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P, Ribera JM, Hernandez JM, Lahuerta JJ, Orfao A, et al. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005;90:1365–1372.
62. de Tute RM, Jack AS, Child JA Morgan GJ, Owen RG Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007;21:2046–2049.
63. Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol 2009;132:728–732.
64. Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, et al. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma. Haematologica 2015;100:e53–55.
65. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, Fumero S, Jimenez C, Alcoceba M, Chillon MC, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014;28:391–397.
66. Robillard N, Bene MC, Moreau P, Wuilleme S. A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013;3:e134.
67. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712–2717.
68. Flores-Montero J. Automated, highly-sensitive flow cytometry method for standardized detection of minimal residual disease in multiple myeloma. Manuscript in Preparation.
69. Domingo E, Moreno C, Sanchez-Ibarrola A, Panizo C, Paramo JA, Merino J. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica 2010;95:691–692.
70. Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B, Barnett D, Arroz M, Wallace P, Durie B, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol 2014;89:1159–1160.
71. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, Mateos MV, Cibeira MT, Cordon L, Oriol A, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687–691.
72. Paiva B, Montalbán MA, Puig N, Cordon L, Martinez-Lopez J, Ocio EM, Hernandez M, Teruel AI, Gironella M, Echeveste MA, et al. Clinical significance of sensitive flow-MRD monitoring in elderly multiple myeloma patients on the pethema/GEM2010MAS65 trial. Blood 2014;124:3390.
73. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, et al. Response assessment in Waldenstrom macroglobulinaemia: Update from the VIth International Workshop. Br J Haematol 2013;160:171–176.
74. Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S, Almeida J, Del Carmen Garcia-Macias M, Bottcher S, Van Dongen JJ, et al. Automated pattern-guided principal component analysis vs. expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: A step forward in the standardization of clinical immunophenotyping. Leukemia 2010;24:1927–1933.
75. European scientific foundation of laboratory hemato oncology (ESLHO). New Developments in the ESLHO Networks. 3rd ESLHO Symposium. The Nederlands; 2014. 63 p.